Anika Therapeutics, Inc. (ANIK) Tops Q3 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq climbs over 1% as SpaceX, Super Micro improve AI sentiment
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $20.51 +0.34%
Revenue Growth %: +5.9%
Financial Fact:
Cost of product revenue: 5M
Today's EPS Names:
OMID, BCML, CZNC, More
Revenue Growth %: +5.9%
Financial Fact:
Cost of product revenue: 5M
Today's EPS Names:
OMID, BCML, CZNC, More
Join SI Premium – FREE
Anika Therapeutics, Inc. (NASDAQ: ANIK) reported Q3 EPS of $0.40, $0.07 better than the analyst estimate of $0.33. Revenue for the quarter came in at $22.1 million versus the consensus estimate of $20.33 million.
For earnings history and earnings-related data on Anika Therapeutics, Inc. (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Plumas Bancorp (PLBC) Tops Q3 EPS by 15c
- Netflix shares slide after weak guidance overshadows earnings beat
- eBay to cut 9% of workforce in strategic operational push, Reuters reports
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
